Vaccines Based on Whole Recombinant Saccharomyces Cerevisiae Cells

FEMS Yeast Res. 2010 Dec;10(8):1060-9. doi: 10.1111/j.1567-1364.2010.00665.x.

Abstract

The ultimate goal of therapeutic vaccines is to activate and exploit the patient's own immune system to vigorously and dynamically seek and eradicate established malignant or virally infected cells. Therapeutic vaccines also offer the potential for preventing disease recurrence. Saccharomyces cerevisiae-based vaccines, where the yeast is engineered to express viral or tumor antigens, represent an ideal therapeutic approach due to their ability to stimulate tumor- or viral-specific CD4(+) and CD8(+) T-cell responses that are capable of reducing disease burden. This review describes preclinical and clinical studies supporting the development of S. cerevisiae-based therapeutic vaccines for the treatment of cancer and viral diseases, as well as multimodal strategies in which therapeutic vaccines are combined with cytotoxic drugs to achieve a greater clinical response.

Publication types

  • Review

MeSH terms

  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology*
  • Antigens, Neoplasm / metabolism
  • Antigens, Viral / genetics
  • Antigens, Viral / immunology*
  • Antigens, Viral / metabolism
  • CD4-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / immunology
  • Drug Carriers*
  • Fungal Vaccines / genetics
  • Fungal Vaccines / immunology*
  • Genetic Vectors*
  • Humans
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Saccharomyces cerevisiae / genetics*
  • Saccharomyces cerevisiae / metabolism*
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / metabolism

Substances

  • Antigens, Neoplasm
  • Antigens, Viral
  • Drug Carriers
  • Fungal Vaccines
  • Recombinant Proteins
  • Vaccines, Synthetic